Company intelligence / Profile preview

A-Mansia Biotech

Mont-Saint Guibert / Louvain-la-Neuve area, Walloon Brabant / Brabant Wallon, Belgiuma-mansia.com ↗

Ownership: Private
Development stage: Other

Overview

A-Mansia’s lead product—pasteurised Akkermansia muciniphila—received EFSA approval as a novel food ingredient. Human studies have shown it can help prevent deterioration of metabolic health in at-risk subjects by improving gut barrier function and reducing inflammation. The company has launched a commercial dietary supplement targeting weight management and glucose control in Europe. Pharmaceutical programs are in earlier stages.[1][2][3]

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Pasteurised live biotherapeutic products (bacterial supplements)dietary supplements based on *Akkermansia muciniphila*
Industry: Biotech

Partnerships

Collaborations with Université catholique de Louvain (UCLouvain)Wageningen Universitycontract organizations for R&D[2]

Beyond the preview

Go deeper on A-Mansia Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-Mansia Biotech.